LC
CGEM icon

Lindbrook Capital’s Cullinan Oncology CGEM Stock Holding History

Lindbrook Capital’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$1.2K Sell
158
-133
-46% -$1.28K ﹤0.01% 2413
2024
Q4 		$3.54K Sell
291
-28
-9% -$402 ﹤0.01% 2123
2024
Q3 		$5.34K Buy
319
+28
+10% +$497 ﹤0.01% 1986
2024
Q2 		$5.08K Hold
291
– – ﹤0.01% 1985
2024
Q1 		$4.96K Hold
291
– – ﹤0.01% 1893
2023
Q4 		$2.96K Buy
+291
New +$2.58K ﹤0.01% 2119
2023
Q3 		– Sell
-154
Closed -$1.66K – 2705
2023
Q2 		$1.66K Sell
154
-233
-60% -$2.48K ﹤0.01% 2223
2023
Q1 		$3.96K Buy
387
+2
+0.5% +$22 ﹤0.01% 1953
2022
Q4 		$4.06K Buy
385
+207
+116% +$2.52K ﹤0.01% 1926
2022
Q3 		$2K Hold
178
– – ﹤0.01% 2015
2022
Q2 		$2K Buy
178
+33
+23% +$374 ﹤0.01% 1925
2022
Q1 		$2K Buy
+145
New +$1.96K ﹤0.01% 1958

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Lindbrook Capital's CGEM Position: Q1 2025 in Review

Lindbrook Capital reduced its Cullinan Oncology (CGEM) stake by 46% in Q1 2025, selling an estimated $1.28K and leaving 158 shares worth $1.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2413.

Lindbrook Capital first reported a position in CGEM in Q1 2022 and has held it in 12 quarters since. The position peaked at $5.34K in Q3 2024. 148 funds tracked by Wall St. Rank hold CGEM as of Q1 2025.

  • Lindbrook Capital held 158 shares of Cullinan Oncology worth $1.2K as of Q1 2025.
  • Lindbrook Capital sold 133 Cullinan Oncology shares in Q1 2025, an estimated $1.28K.
  • Cullinan Oncology made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2413 holding.
  • Lindbrook Capital first reported a position in Cullinan Oncology in Q1 2022 and has held it in 12 quarters since.
  • Lindbrook Capital's Cullinan Oncology position peaked at $5.34K in Q3 2024.
  • 148 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.